Focused Wealth Management Inc Has $415,000 Stock Holdings in Prothena Co. plc (NASDAQ:PRTA)

Focused Wealth Management Inc boosted its holdings in shares of Prothena Co. plc (NASDAQ:PRTA) by 98.7% in the second quarter, according to its most recent filing with the SEC. The firm owned 20,129 shares of the biotechnology company’s stock after acquiring an additional 10,000 shares during the period. Focused Wealth Management Inc’s holdings in Prothena were worth $415,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. Price T Rowe Associates Inc. MD grew its holdings in Prothena by 10.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,237,351 shares of the biotechnology company’s stock worth $153,986,000 after acquiring an additional 417,338 shares during the period. Wellington Management Group LLP grew its holdings in Prothena by 21.1% during the 4th quarter. Wellington Management Group LLP now owns 2,594,102 shares of the biotechnology company’s stock worth $94,270,000 after acquiring an additional 452,455 shares during the period. Vanguard Group Inc. grew its holdings in Prothena by 5.1% during the 1st quarter. Vanguard Group Inc. now owns 1,125,283 shares of the biotechnology company’s stock worth $27,873,000 after acquiring an additional 54,728 shares during the period. Artal Group S.A. grew its holdings in Prothena by 99.7% during the 1st quarter. Artal Group S.A. now owns 1,001,360 shares of the biotechnology company’s stock worth $24,804,000 after acquiring an additional 500,000 shares during the period. Finally, Boxer Capital LLC grew its holdings in Prothena by 6.4% during the 4th quarter. Boxer Capital LLC now owns 665,000 shares of the biotechnology company’s stock worth $24,166,000 after acquiring an additional 40,000 shares during the period. Institutional investors and hedge funds own 97.08% of the company’s stock.

Prothena Stock Up 3.3 %

PRTA opened at $22.27 on Friday. Prothena Co. plc has a 12 month low of $18.69 and a 12 month high of $56.27. The firm’s fifty day simple moving average is $21.63 and its 200 day simple moving average is $22.93.

Prothena (NASDAQ:PRTA) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $1.22 EPS for the quarter, beating the consensus estimate of ($1.01) by $2.23. The business had revenue of $132.01 million for the quarter, compared to analysts’ expectations of $10.73 million. Prothena had a negative net margin of 23.44% and a negative return on equity of 9.00%. The firm’s revenue was up 3184.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.03) EPS. On average, research analysts predict that Prothena Co. plc will post -2.58 earnings per share for the current year.

Wall Street Analyst Weigh In

PRTA has been the subject of several research analyst reports. StockNews.com raised shares of Prothena from a “sell” rating to a “hold” rating in a report on Monday, August 12th. Oppenheimer decreased their price target on shares of Prothena from $66.00 to $62.00 and set an “outperform” rating for the company in a report on Wednesday, August 14th. JMP Securities decreased their price target on shares of Prothena from $85.00 to $83.00 and set a “market outperform” rating for the company in a report on Thursday, May 9th. Royal Bank of Canada decreased their price target on shares of Prothena from $28.00 to $24.00 and set a “sector perform” rating for the company in a report on Friday, August 9th. Finally, HC Wainwright decreased their price target on shares of Prothena from $90.00 to $84.00 and set a “buy” rating for the company in a report on Thursday, May 9th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $62.86.

Prothena Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.